

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/53, 9/02	A1	(11) International Publication Number: WO 97/09431 (43) International Publication Date: 13 March 1997 (13.03.97)
(21) International Application Number: PCT/US96/14087 (22) International Filing Date: 3 September 1996 (03.09.96) (30) Priority Data: 60/003,142 1 September 1995 (01.09.95) US (71) Applicant: NOVO NORDISK BIOTECH, INC. [US/US]; 1445 Drew Avenue, Davis, CA 95616-4880 (US). (72) Inventors: XU, Feng; 1534 Carmel Valley Drive, Woodland, CA 95776 (US). BERKA, Randy, M.; 3609 Modoc Place, Davis, CA 95616 (US). WAHLEITHNER, Jill, Angela; 1718 Tea Place, Davis, CA 95616 (US). (74) Agents: ZELSON, Steve, T. et al.; Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY 10174 (US).		(81) Designated States: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: BLUE COPPER OXIDASE MUTANTS WITH ENHANCED ACTIVITY		
(57) Abstract The present invention relates to mutants of a blue multi-copper oxidase, comprising (a) a substitution of one or more amino acid residues with other amino acid residues, (b) and insertion of one or more amino acid residues and/or (c) a deletion of one or more amino acid residues, wherein the substitution, insertion or deletion is carried out at a position which is located no greater than 15Å from a Type I (T1) copper site. The present invention also relates to nucleic acid constructs comprising a nucleic acid sequence encoding the mutants of the present invention, host cells comprising the construct of the present invention, and methods for producing mutants of the present invention.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CN	Cameroon	LR	Liberia	SN	Senegal
CM	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

BLUE COPPER OXIDASE MUTANTS WITH ENHANCED ACTIVITY

Background of the Invention

5 Field of the Invention

The present invention relates to mutant multi-copper oxidases. More specifically, the invention relates to oxidases which have been modified so as to exhibit altered pH activity profiles relative to the wild-type oxidase.

10 Description of the Related Art

There are currently a number of well-known blue copper oxidases which have various commercial/industrial applications. Two major classes of these enzymes are recognized: (1) the single copper proteins, which are single copper-containing, blue electron-transfer proteins such as plastocyanin, azurin, stellacyanin, amicyanin, auracyanin, cucumber basic blue, 15 mavicyanin, rusticyanin, and umecyanin; and (2) the multi-copper oxidases, which are multiple copper-containing, blue oxidoreductases such as laccase, bilirubin oxidase, phenoxazinone synthase, ascorbate oxidase, ceruloplasmin, and nitrite reductase. The blue color of these proteins arises from the so-called Type 1 (T1) copper site.

It is an object of the present invention to provide mutants of blue multi-copper 20 oxidases which have improved properties.

Brief Description of the Figures

Figure 1 shows the scheme for construction of intermediate plasmid pInt2.22 and 25 oligonucleotide-directed mutagenesis of the *Myceliophthora thermophila lcc-1* gene.

Figure 2 shows the construction of the intermediate pInt1 which contains the *Aspergillus oryzae* TAKA amylase promoter and 5'-portion of the *Myceliophthora thermophila lcc-1* coding region.

Figure 3 shows the final step in construction of pRaMB17 and its derivatives, 30 pRaMB17M and pRaMB17Q, which direct expression of wild-type and mutant forms of *Myceliophthora thermophila* laccase (MtL).

Figure 4 shows the construction of pBANE22T which directs expression of a mutant form of *Myceliophthora thermophila* laccase.

Figure 5 shows the pH activity profiles of the wild-type (wt) and mutant *Rhizoctonia solani* laccases (RsLs) and *Myceliophthora thermophila* laccases (MtLs): wt (—); mutant M (—); mutant T (.....); (A), RsL with 2,2'-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS); (B), RsLs with syringaldazine (SGZ); (C), MtLs with ABTS; (D), MtLs with SGZ.

Figure 6 shows the nucleotide sequence and the deduced amino acid sequence of *Rhizoctonia solani* laccase isozyme 4 (*rsl4*) gene (SEQ ID NOS:24 and 25).

Figure 7 shows the nucleotide sequence and the deduced amino acid sequence of *Myceliophthora thermophila* laccase *lcc-1* gene (SEQ ID NOS:26 and 27).

Summary of the Invention

The present invention relates to mutants of a blue multi-copper oxidase, comprising a mutation selected from the group consisting of (a) a substitution of one or more amino acid residues with other amino acid residues, (b) an insertion of one or more amino acid residues and/or (c) a deletion of one or more amino acid residues, wherein the substitution, insertion or deletion is carried out at a position which is located no greater than 15Å from a Type I (T1) copper site. The present invention also relates to nucleic acid constructs comprising a nucleic acid sequence encoding the mutants of the present invention, host cells comprising the construct of the present invention, and methods for producing mutants of the present invention.

Detailed Description of the Invention

The present invention relates to mutants of a blue multi-copper oxidase, comprising (a) a substitution of one or more amino acid residues with other amino acid residues, (b) an insertion of one or more amino acid residues and/or (c) a deletion of one or more amino acid residues, wherein the substitution, insertion or deletion is carried out at a position which is located no greater than 20Å from a Type I (T1) copper site. Preferably, each mutation is a substitution of one or more amino acid residues with other amino acid residues.

The Type 1 copper site consists of four ligands which bind to a copper ion, each of which is either an amino acid residue of the blue copper oxidase or a small molecule such

as a water molecule. A ligand is defined herein an amino acid residue of a blue copper oxidase which binds to a copper ion. The Type I copper site of all known blue copper oxidases consists of the following ligands: two histidines (H), one cysteine (C), and, possibly, one additional methionine.

5 The ligand location for *Rhizoctonia solani* is: H 427, C 480, H 485 and possibly L 470 and for *Myceliophthora thermophilum* is H 431, C 503, H 508 and possibly L 513.

For purposes of the present invention, the distance from a Type I copper site is measured from the copper ion.

10 In a preferred embodiment, the mutant has a mutation at a position which is located no greater than 15Å from a Type I copper site. In another preferred embodiment, the mutant has a mutation at a position which is located no greater than 12Å from a Type I copper site. In another preferred embodiment, the mutant has a mutation at a position which is located no greater than 10Å from a Type I copper site. In another preferred embodiment, the mutant has a mutation at a position which is located no greater than 8Å from a Type I copper site. 15 In another preferred embodiment, the mutant has a mutation at a position which is located no greater than 6Å from a Type I copper site. In another preferred embodiment, the mutant has a mutation at a position which is located no greater than 4Å from a Type I copper site. In another preferred embodiment, the mutant has a mutation at a position which is located no greater than 2.5Å from a Type I copper site. In another preferred embodiment, the mutant has a mutation of an amino acid residue which is adjacent to a Type I copper site ligand. In another preferred embodiment, the mutant has a mutation of an amino acid residue which is a Type I copper site ligand. 20

The mutants of the present invention are mutants of a blue multi-copper oxidase. Preferably, the blue multi-copper oxidase is a bilirubin oxidase (Kokeida *et al.*, 1993, 25 *Journal of Biological Chemistry* 268: 18801-18809). In another preferred embodiment, the blue multi-copper oxidase is a phenoxazinone synthase (Freeman *et al.*, 1993, *Biochemistry* 32: 4826-4830). In another preferred embodiment, the blue multi-copper oxidase is an ascorbate oxidase (Tauber *et al.*, 1935, *Journal of Biological Chemistry* 110: 211). In another preferred embodiment, the blue multi-copper oxidase is a ceruloplasmin (Curzon and 30 Young, 1972, *Biochimica Biophysica Acta* 268: 41). In another preferred embodiment, the blue multi-copper oxidase is a nitrite reductase (Godden *et al.*, 1991, *Science* 253: 438-442). In another preferred embodiment, the blue multi-copper oxidase is a laccase. In a most

preferred embodiment, the blue multi-copper oxidase is a fungal laccase, *e.g.*, a *Rhizoctonia* laccase (preferably a *Rhizoctonia solani* laccase or RsL; WO 95/07988) or a *Myceliophthora* laccase (preferably a *Myceliophthora thermophilum* laccase or MtL described in U.S. application Serial No. 08/253,781, which is incorporated herein by reference).

5 In another preferred embodiment, the oxidase is another *Rhizoctonia* laccase (as disclosed in U.S. application Serial No. 08/172,331, which is incorporated herein by reference), another *Myceliophthora* laccase (as disclosed in U.S. application Serial No. 08/253,781, which is incorporated herein by reference), and laccases of *Polyporus* (as disclosed in U.S. application Serial No. 08/441,147, which is incorporated herein by reference), *Trametes*, *Pyricularia*, *Coriolus*, *Scytalidium* (as disclosed in U.S. application Serial No. 08/253,784, which is incorporated herein by reference), *Rigidoporus* and *Phenllinus* (Geiger *et al.*, 1986, *Appl. Biochem. Biotech.*, 13: 97-110), *Podospora* (Moltitoris and Reinhammar, 1974, *Biochimica Biophysica Acta* 386: 493-502), *Lentinus* (Leatham and Stahmann, 1980, *Journal of General Microbiology* 125: 147-157), *Neurospora* (Germann *et al.*, 1987, *Journal of Biological Chemistry* 263: 885-896), *Aspergillus* (Kurtz and Champe, 1982, *Journal of Bacteriology* 151: 1338-1345), *Phlebia* (Niku-Paavola *et al.*, 1988, *Biochemical Journal* 254:877-884), *Botrytis* (Dubernet *et al.*, 1976, *Phytochemistry* 16: 191-193), *Sclerotia* (Chet and Huttermann, 1982, *FEMS Microbiological Letters* 14: 211-215), *Curvularia* (Banerjee and Vohra, 1991, *Folia Microbiol.* 36: 343-346), *Fomes* (Haars and 10 Huttermann, 1983, *Arch. Microbiol.* 134: 309-313), *Schizophyllum* (De Vries *et al.*, 1986, *Journal of General Microbiology* 132: 2817-2826), *Cerrena* (Bekker *et al.*, 1990, *Biokhimia* 55: 2019-2024), *Armillaria* (Rehman and Thurston, 1992, *Journal of General Microbiology* 138: 1251-1257), *Agaricus* (Perry *et al.*, 1993, *Journal of General Microbiology* 139: 1209-1218), *Pleurotus* (Von Hunolstein *et al.*, 1986, *Journal of General Applied Microbiology* 32: 185-191), *Acer pseudopaltanus* (Lafayette *et al.*, 1995, *Plant Physiology* (Rockville) 107: 667-668), and *Rhus* (Bertrand, 1895, *C. R. Acad. Sci. Paris* 121: 166).

The mutants of the present invention may have a different specific activity than the wild-type blue copper oxidases. For example, a negative charge, or more precisely, a relatively high electron density, in the T1 copper site region is important for activity.

30 Furthermore, the mutants of the present invention may have a different pH-activity profile than the wild-type blue copper oxidases, *e.g.*, the mutants can have a higher or lower pH optimum by an alteration of the charge distribution (or dielectric anisotropy) at the T1

copper site. In order to enhance the activity of the oxidase of interest in a more alkaline pH range, electron density and/or negative charge should be increased. Thus, in the mutants of the present invention, (a) a neutral amino acid residue is substituted with a negative amino acid residue or (b) a positive amino acid residue is substituted with a negative or neutral amino acid residue. In addition, neutral residues equipped with a functional group that bear a relatively high electron density and could act as general base, such as histidine, serine, threonine, tyrosine, cysteine, and methionine, may also be used to substitute other neutral residues possessing only simple aliphatic or aromatic side chains, such as leucine and phenylalanine. In order to enhance the activity of the oxidase of interest in a more acidic pH range, electron density and/or negative charge should be decreased. Thus, in this embodiment of the mutants of the present invention, (a) a neutral amino acid residue is substituted with a positive amino acid residue or (b) a negative amino acid residue is substituted with a positive or neutral amino acid residue.

The present invention also relates to mutants which can be expressed in higher yields. Such mutants include oxidases comprising a substitution of a phenylalanine with another amino acid residue. For example, substituting phenylalanine at a position corresponding to residue 513 of *Myceliophthora thermophila* laccase and position 470 in *Rhizoctonia solani* isozyme 4 laccase results in a low expression yield. Thus, the mutants of the present invention encompass substitutions of Phe at one of these positions with another amino acid residue. Preferably, the amino acid residue does not ligate to copper, *i.e.*, the amino acid residue is not histidine, cysteine, methionine, glutamate, and aspartate. Preferably, phenylalanine is substituted by leucine. In a preferred embodiment, the yield of the mutant enzyme is increased at least two-fold, more preferably at least five-fold, over the yield observed with the corresponding wild-type enzyme when both are expressed in the same host and fermented under the same conditions.

In a preferred embodiment, the mutants of the present invention comprise a mutation in a region corresponding to: (a) the segment that contains one Cu-ligating His, *e.g.*, 416VIELNITGGADHPI429 of *Rhizoctonia solani* laccase and 421ENDPGAPFTLPHPM433 of *Myceliophthora thermophila* laccase; (b) the segment that contains another ligating His and the ligating Cys, *e.g.*, 474GPWFVHCHIDWHLEAGLALVF494 of *Rhizoctonia solani* laccase and 497GAWLFHCHIAWHVSGGLGV515 of *Myceliophthora thermophila* laccase; (c) the segment corresponding to the sequence where Q353 and W362 of ascorbate oxidase

reside, *e.g.*, 356VSLNLAIGRSTVDGIL371 of *Rhizoctonia solani* laccase and 361VTLDTTGTPLFVWKN376 of *Myceliophthora thermophila* laccase; (d) the segment corresponding to the sequence where R285 of ascorbate oxidase resides, *e.g.*, 303LDPTNVFAVL312 of *Rhizoctonia solani* laccase and 308AIFHYAGAPG317 of *Myceliophthora thermophila* laccase; (e) the segment corresponding to the sequence where W163 of ascorbate oxidase resides, *e.g.*, 217INVKRGKRYR226 of *Rhizoctonia solani* laccase and 222GRRHRLRLIN231 of *Myceliophthora thermophila* laccase; and (f) the segment corresponding to 465LEAGL472, more preferably 466LEAGL470, of *Rhizoctonia solani* laccase. Those skilled in the art will readily recognize, by routine homology alignment, the corresponding regions in other blue copper oxidases. In a preferred embodiment, the mutants comprise a mutation in the segment corresponding to 416VIELNITGGADHPI429 of *Rhizoctonia solani* laccase and 421ENDPGAPFTLPHPM433 of *Myceliophthora thermophila* laccase.

In a preferred embodiment, the mutants comprise at least two amino acid residues, more preferably at least 3 amino acid residues. In another preferred embodiment, the mutants comprise five mutations, more preferably four mutations, even more preferably three mutations, even more preferably two mutations, and most preferably one mutation.

The mutants described herein are most efficiently prepared by site-directed mutagenesis of the DNA encoding the wild-type laccase of interest. Such techniques are well-known in the art, and are described in, for example, Sambrook *et al.*, 1989, *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. The present invention also encompasses the nucleic acid encoding the mutant laccases, as well as vectors and host cells comprising same, for use in recombinant expression of the mutant enzyme.

The choice of host cells and expression vectors will to a large extent depend upon the enzyme of choice and its source. The mutant gene can be expressed, in active form, using an expression vector. A useful expression vector contains an element that permits stable integration of the vector into the host cell genome or autonomous replication of the vector in a host cell independent of the genome of the host cell, and preferably one or more phenotypic markers which permit easy selection of transformed host cells. The expression vector may also include control sequences encoding a promoter, ribosome binding site, translation initiation signal, and, optionally, a repressor gene, a selectable marker or various

activator genes. To permit the secretion of the expressed protein, nucleotides encoding a signal sequence may be inserted prior to the coding sequence of the gene. For expression under the direction of control sequences, a laccase gene to be used according to the invention is operably linked to the control sequences in the proper reading frame. Promoter sequences that can be incorporated into plasmid vectors, and which can direct the transcription of the laccase gene, include, but are not limited to, the prokaryotic β -lactamase promoter (Villa-Kamaroff *et al.*, 1978, *Proceedings of the National Academy of Sciences USA* 75: 3727-3731) and the *tac* promoter (DeBoer *et al.*, 1983, *Proceedings of the National Academy of Sciences USA* 80: 21-25). Further references can also be found in "Useful proteins from recombinant bacteria" in 1980, *Scientific American* 242: 74-94; and in Sambrook *et al.*, 1989, *supra*.

The expression vector carrying the nucleic acid construct of the invention may be any vector which may be conveniently subjected to recombinant DNA procedures. The vector may be an autonomously replicating vector, *i.e.*, a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, *e.g.*, a plasmid, or an extrachromosomal element, minichromosome or an artificial chromosome. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.

In the vector, the nucleic acid sequence should be operably connected to a suitable promoter sequence. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the DNA construct of the invention, especially in a bacterial host, are the promoter of the *lac* operon of *E. coli*, the *Streptomyces coelicolor* agarase gene *dagA* promoters, the promoters of the *Bacillus licheniformis* alpha-amylase gene (*amyL*), the promoters of the *Bacillus stearothermophilus* maltogenic amylase gene (*amyM*), the promoters of the *Bacillus amyloliquefaciens* alpha-amylase (*amyQ*), or the promoters of the *Bacillus subtilis* *xylA* and *xylB* genes. In a yeast host, a useful promoter is the ENO-1 promoter. For transcription in a fungal host, examples of useful promoters are those derived from the gene encoding *Aspergillus oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *Aspergillus niger* neutral alpha-amylase, *Aspergillus niger* acid stable alpha-amylase, *Aspergillus niger* or *Aspergillus awamori* glucoamylase (*glaA*), *Rhizomucor miehei* lipase,

Aspergillus oryzae alkaline protease, *Aspergillus oryzae* triose phosphate isomerase or *Aspergillus nidulans* acetamidase. Preferred are the TAKA-amylase and *glaA* promoters.

The expression vector of the invention may also comprise a suitable transcription terminator and, in eukaryotes, polyadenylation sequences operably connected to the DNA sequence encoding the laccase of the invention. Termination and polyadenylation sequences may suitably be derived from the same sources as the promoter. The vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUB110, pE194, pAMB1 and pIJ702.

The vector may also comprise a selectable marker, *e.g.*, a gene the product of which complements a defect in the host cell, such as the *dal* genes from *Bacillus subtilis* or *Bacillus licheniformis*, or one which confers antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracycline resistance. Examples of *Aspergillus* selection markers include *amdS*, *pyrG*, *argB*, *niaD*, *sC*, and *hygB* a marker giving rise to hygromycin resistance. Preferred for use in an *Aspergillus* host cell are the *amdS* and *pyrG* markers of *Aspergillus nidulans* or *Aspergillus oryzae*. A frequently used mammalian marker is the dihydrofolate reductase (DHFR) gene. Furthermore, selection may be accomplished by co-transformation, *e.g.*, as described in WO 91/17243.

It is generally preferred that expression gives rise to a product that is extracellular. The laccases of the present invention may thus comprise a preregion permitting secretion of the expressed protein into the culture medium. If desirable, this preregion may be native to the laccase of the invention or substituted with a different preregion or signal sequence, conveniently accomplished by substitution of the DNA sequences encoding the respective preregions. For example, the preregion may be derived from a glucoamylase or an amylase gene from an *Aspergillus* species, an amylase gene from a *Bacillus* species, a lipase or proteinase gene from *Rhizomucor miehei*, the gene for the alpha-factor from *Saccharomyces cerevisiae*, or the calf preprochymosin gene. Particularly preferred, when the host is a fungal cell, is the preregion for *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* neutral amylase, the maltogenic amylase form *Bacillus* NCIB 11837, *Bacillus stearothermophilus* alpha-amylase, or *Bacillus licheniformis* subtilisin. An effective signal sequence is the *Aspergillus oryzae* TAKA amylase signal, the *Rhizomucor miehei* aspartic proteinase signal, and the *Rhizomucor miehei* lipase signal.

The procedures used to ligate the nucleic acid construct of the invention, the promoter, terminator and other elements, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (*cf.*, for instance, Sambrook *et al.*, 1989, *supra*).

5 The cell of the invention either comprising a nucleic acid construct or an expression vector of the invention as defined above is advantageously used as a host cell in the recombinant production of an enzyme of the invention. The cell may be transformed with the nucleic acid construct of the invention, conveniently by integrating the construct into the host chromosome. This integration is generally considered to be an advantage as the
10 sequence is more likely to be stably maintained in the cell. Integration of the constructs into the host chromosome occurs by homologous or heterologous recombination. Alternatively, the cell may be transformed with an expression vector as described above in connection with the different types of host cells.

The host cell may be selected from prokaryotic cells, such as bacterial cells.
15 Examples of suitable bacteria are gram positive bacteria such as *Bacillus subtilis*, *Bacillus licheniformis*, *Bacillus lentus*, *Bacillus brevis*, *Bacillus stearothermophilus*, *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus coagulans*, *Bacillus circulans*, *Bacillus lautus*, *Bacillus megaterium*, *Bacillus thuringiensis*, or *Streptomyces lividans* or *Streptomyces murinus*, or gram negative bacteria such as *E. coli*. The transformation of the bacteria may,
20 for instance, be effected by protoplast transformation or by using competent cells in a manner known *per se*.

The host cell is preferably a eukaryote, such as mammalian cells, insect cells, plant cells or preferably fungal cells, including yeast and filamentous fungi. For example, useful mammalian cells include CHO or COS cells. A yeast host cell may be selected from a
25 species of *Saccharomyces* or *Schizosaccharomyces*, *e.g.*, *Saccharomyces cerevisiae*. Useful filamentous fungi may be selected from a species of *Aspergillus*, *e.g.*, *Aspergillus oryzae* or *Aspergillus niger*. Alternatively, a strain of a *Fusarium* species, *e.g.*, *Fusarium oxysporum*, or *Fusarium graminearum*, can be used as a host cell. Fungal cells may be transformed by a process involving protoplast formation and transformation of the protoplasts followed by
30 regeneration of the cell wall in a manner known *per se*. A suitable procedure for transformation of *Aspergillus* host cells is described in EP 238 023. A suitable method of

transforming *Fusarium* species is described by Malardier *et al.*, 1989, *Gene* 78:147-156 or in copending U.S. application Serial No. 08/269,449.

The present invention thus also provides a method of producing a recombinant protein of the invention, which method comprises cultivating a host cell as described above under conditions conducive to the production of the enzyme and recovering the enzyme from the cells and/or culture medium. The medium used to cultivate the cells may be any conventional medium suitable for growing the host cell in question and obtaining expression of the laccase of the invention. Suitable media are available from commercial suppliers or may be prepared according to published formulae (*e.g.*, in catalogues of the American Type Culture Collection).

The resulting enzyme may be recovered from the medium by conventional procedures including separating the cells from the medium by centrifugation or filtration, precipitating the proteinaceous components of the supernatant or filtrate by means of a salt, *e.g.*, ammonium sulphate, followed by purification by a variety of chromatographic procedures, *e.g.*, ion exchange chromatography, gel filtration chromatography, affinity chromatography, or the like. Preferably, the isolated protein is about 90% pure as determined by SDS-PAGE, purity being most important in food, juice or detergent applications.

In a particularly preferred embodiment, the expression of the enzyme is achieved in a fungal host cell, such as *Aspergillus*. As described in detail in the following examples, the laccase gene is ligated into a plasmid containing the *Aspergillus oryzae* TAKA alpha-amylase promoter, and the *Aspergillus nidulans amdS* selectable marker. Alternatively, the *amdS* may be on a separate plasmid and used in co-transformation. The plasmid (or plasmids) is used to transform an *Aspergillus* species host cell, such as *Aspergillus oryzae* or *Aspergillus niger* in accordance with methods described in Yelton *et al.*, 1984, *Proceedings of the National Academy of Sciences USA* 81: 1470-1474.

The modified oxidases, particularly laccases of the present invention can be used in a number of industrial methods. These processes include polymerization of lignin, both Kraft and lignosulfates, in solution, in order to produce a lignin with a higher molecular weight. Such methods are described in, for example, Jin *et al.*, 1991, *Holzforschung* 45: 467-468; U.S. Patent No. 4,432,921; EP 0 275 544; PCT/DK93/00217, 1992.

The oxidases of the present invention can also be used for in situ depolymerization of lignin in Kraft pulp, thereby producing a pulp with lower lignin content. This use of these

enzymes is an improvement over the current use of chlorine for depolymerization of lignin, which leads to the production of chlorinated aromatic compounds, which are an environmentally undesirable by-product of paper mills. Such uses are described in, for example, *Current Opinion in Biotechnology* 3: 261-266, 1992; *Journal of Biotechnology* 25: 333-339, 1992; Hiroi *et al.*, 1976, *Svensk Papperstidning* 5: 162-166.

Oxidation of dyes or dye precursors and other chromophoric compounds leads to decolorization of the compounds. Laccase can be used for this purpose, which can be particularly advantageous in a situation in which a dye transfer between fabrics is undesirable, *e.g.*, in the textile industry and in the detergent industry. Methods for dye transfer inhibition and dye oxidation can be found in WO 92/01406, WO 92/18683, EP 0495836 and Calvo, 1991, *Mededelingen van de Faculteit Landbouwwetenschappen/Rijksuniversiteit Gent*. 56: 1565-1567; Tsujino *et al.*, 1991, *Journal of the Chemical Society* 42: 273-282; methods for the use of oxidation of dye and dye precursors in hair coloring are found in U.S. application Serial No. 08/441,146 and 441,147, the contents of which are incorporated herein by reference.

The present laccase can also be used for the polymerization of phenolic or aniline compounds present in liquids. An example of such utility is the treatment of juices, such as apple juice, so that the laccase will accelerate a precipitation of the phenolic compounds present in the juice, thereby producing a more stable juice. Such applications have been described in Stutz, 1993, *Fruit Processing* 7/93, 248-252; Maier *et al.*, 1990, *Dr. Lebensmittel-rundschau* 86: 137-142; Dietrich *et al.*, 1990, *Fluss. Obst* 57: 67-73.

The present invention is further explained in the following non-limiting examples.

Examples

Materials and methods

Chemicals used as buffers and substrates are commercial products of at least reagent grade.

The protocols for molecular biology experiments (including restriction digests, DNA ligations, gel electrophoresis, and DNA preparations) are adapted from either the instructions of the manufacturer or standard procedures (Sambrook *et al.*, 1989, *supra*). All oligonucleotides are synthesized by an Applied Biosystems 294 DNA/RNA Synthesizer.

Nucleotide sequences are determined by an Applied Biosystems automatic DNA Sequencer, Model 373A, version 1.2.0.

Example 1: Site-directed mutagenesis of *Myceliophthora thermophila* laccase

The construction of a *Myceliophthora thermophila* laccase expression vector, pRaMB17, and several derivatives, pRaMB17M, pBANE22T, and pRaMB17Q, which direct expression of the *Myceliophthora thermophila* wild-type laccase and laccase variants, is shown in Figures 1-4. The primers used in the constructions are summarized in Table 1.

Table 1 - Primers

Primer	Sequence
1 (forward) 5'	dGTCGTCTACCTCGAGCGCGCC 3' (SEQ ID NO:1)
2 (reverse) 5'	dGTCATCTAGACGCTCACGCCTTGACCAGCCA 3' (SEQ ID NO:2)
3 5'	dGTAGACGACGCCGAAGCCGCCGAGAC 3' (SEQ ID NO:3)
4 5'	dGACGACGCCAGGCCAGCCTCGAGGTGCCAGGCGATGTG 3' (SEQ ID NO:4)
5 5'	dGAGGTAGACGACGCCGAAGCCAGCCTCGAGGTGCCAGGCGATGTG 3' (SEQ ID NO:5)
6 5'	CGGTACCGTCTAGAGTCGCGATGCATC 3' (SEQ ID NO:6)
7 3'	CCGGGCCATGGCAGATCTCAGCGCTACGTAGGATC 5' (SEQ ID NO:7)
8 5'	ATGATGAAGTCCTTCATCAGCGCCGCGACGCTTTTGGTGGG 3' (SEQ ID NO:8)
9 3'	TACTACTTCAGGAAGTAGTCGCGGCGCTGCGAAAACCAC 5' (SEQ ID NO:9)
10 (forward) 5'	dGGGTCTAGAGGTGACTGACACCTGGCGGT 3' (SEQ ID NO:10)
11 (reverse) 5'	dTGACCCGGGAAGTGGCCCCGACATTCCAGC 3' (SEQ ID NO:11)
12 5'	-gggatttaaatATGAAGTCCTTCATCAGCGCC-3' (SEQ ID NO:12)
13 5'	-gggttaattaaTtACGCCTTGACCAGCCACTCGCC-3' (SEQ ID NO:13)
14 5'	ATACACAAGTGGATGATGAAGTCCTTCATCAGCG 3' (SEQ ID NO:14)

Specifically, a small DNA fragment containing the 3'-terminus of the *lcc-1* coding region (including stop codon) is generated by PCR using pRaMB5 (U.S. application Serial No. 08/441,146, which is incorporated herein by reference) as a template for *Pfu* polymerase with primers 1 and 2 listed in Table 1. The 188 bp PCR product is digested with *Xba*I plus *Xho*I and purified by agarose gel electrophoresis. The purified fragment is then mixed in a three-part ligation reaction with an *Asp*718I-*Xho*I segment (1286 bp) of the *lcc-1* gene from pRaMB5, and pUC518 (a derivative of pUC118; Vieira and Messing, 1987, *Methods in Enzymology* 153: 3-4), containing additional restriction sites for *Bgl*III, *Cla*I, *Xho*I and *Nsi*I in the polylinker, which has been cleaved with *Asp*718I-*Xba*I. The resulting plasmid, pInt2.22, which contains approximately 1.5 kb of the *lcc-1* coding region, is extended from an internal *Asp*718I site through the stop codon which is followed immediately by a *Xba*I site. Single-stranded pInt2.22 DNA template is prepared (Vieira and Messing, 1987, *supra*) and

used as a template for oligonucleotide-directed mutagenesis (Adelman *et al.*, 1983, *DNA* 2: 183-193) with primer 3 for L513F mutation, primer 4 for V509L/S510E/G511A mutation, and primer 5 for V509L/S510E/G511A/L513F mutation to derive the precursor plasmids for pRaMB17, pRaMB17M, pBANE22T and pRaMB17Q.

5 Mutants are identified by hybridization with radiolabeled oligonucleotide primers 3, 4, and 5, and each mutation is verified by DNA sequence analysis.

The next step in the construction of pRaMB17 and its derivatives is partially shown in Figure 2. The starting plasmid, pMWR3-SAN, is prepared by cleaving bacteriophage vector M13mp18 (Yanisch-Perron *et al.*, 1985, *Gene* 33: 103-119) with *Hind*III and *Eco*RI, and purifying the large vector fragment by agarose gel electrophoresis. This fragment is

10 ligated with a synthetic DNA linker having the following sequence:
 5'AATTCGTCGACGGYCTCTATTTCTGTACGGCCTTCAGGTGGCCGCACCGGCCA
 TGCATAGCAGCTGCCAGAGATAAAGACATGCCGGAAGTCCACCGGCGTGGCCG
 GTACGTATTCGA 3' (SEQ ID NO:15)

15 The resulting phage vector, mp18-5'link, is then digested with *Sa*II and *Bsa*I (both sites in the synthetic linker region) and ligated with a 1.1 kb *Sa*II-*Bsa*I fragment from pTAKA-17 comprising the TAKA promoter region to generate the recombinant phage mp18-5'. Plasmid pUC18 (Yanisch-Perron *et al.*, 1985, *supra*) is digested with *Hind*III plus *Eco*RI and the 2.6 kb vector fragment is purified by agarose gel electrophoresis. The isolated

20 fragment is ligated with a synthetic linker with the following sequence:
 5' AATTGTTTAAACTCTAGAGAATTCAAGCTTGTCGACGTTTAAACCAAATTT
 GAGATCTCTTAAGTTCGAACAGCTGCAAATTTGTCGA 3' (SEQ ID NO:16)

The resulting plasmid, pUC18::TAKA-link, is digested with *Sa*II plus *Eco*RI and the vector fragment is isolated by agarose gel electrophoresis. pTAKA-17 is used as a template for PCR amplification of a 0.7 kb TAKA-amylase terminator fragment. For this purpose, the following primers are used:

forward primer: 5' dATGCATAGGGTGGAGAGTATATGATGG 3' (SEQ ID NO:17)

reverse primer: 5' dCTGAATTCCGTTTTCGTTTAC 3' (SEQ ID NO:18)

30 The 0.7 kb product of this PCR reaction is digested with *Nsi*I plus *Eco*RI and mixed in a three-part ligation with *Sa*II and *Eco*RI cleaved pUC18::TAKA-link and the 1.1 kb *Sa*II-*Nsi*I TAKA promoter fragment from mp18-5' to produce pMWR1.

Plasmid pMWRI is modified to generate pMWR3. First, a new TAKA-amylase promoter segment is generated by PCR using pTAKA-17 as a template with the following synthetic primers:

forward primer: 5' dTCCTGCAGAATGCAATTAACTC 3' (SEQ ID NO:19)

5 reverse primer: 5' dCTATGCATATTAAATGCCTTCTGTGGGGTTTATTG 3' (SEQ ID NO:20)

10 The 0.2 kb PCR product is digested with *Nsi*I plus *Pst*I and ligated with the large vector fragment of pMWR1 which has been cleaved with *Nsi*I and *Pst*I. The resulting plasmid, pMWR3, is then modified by inserting a small linker, AATTGGGCCCATGCA (SEQ ID NO:21), which contains an *Apa*I site between the *Swa*I and *Nsi*I sites, creating pMWR3-SAN. A derivative of pMWR3-SAN is then constructed by replacing the *Apa*I-*Xba*I TAKA-amylase terminator fragment with a small linker (primers 6 and 7 shown in Table 1). This linker introduces *Asp*718I, *Xba*I, and *Nru*I cloning sites and inactivates the *Xba*I site of pMWR3-SAN yielding pMWR3L.

15 pMWR3L is digested with *Swa*I and *Asp*718I and mixed in a three-part ligation with a 853 bp *Bsm*I-*Asp*718I fragment comprising the 5'-end of the *lcc-1* coding region and synthetic DNA adapter containing the translation initiation region (primers 8 and 9 shown in Table 1) to yield plasmid pInt1.

20 A 597 bp DNA segment comprising the *Aspergillus niger glaA* terminator region is then isolated by PCR using pHD414 (EP 238 023) as a template with primers 10 and 11 shown in Table 1, which introduce *Xba*I and *Sma*I sites at the 5' and 3'-ends of the terminator, respectively. The amplified DNA fragment is subsequently cleaved with *Xba*I plus *Sma*I and subcloned into pUC118 to generate plasmid pUC::AMGterm.

25 Finally, the 1.5 kb fragments containing the wild-type and mutant *lcc-1* gene sequences are excised by digestion with *Asp*718I and *Xba*I and purified by agarose gel electrophoresis. Each of these fragments is mixed in a three part ligation (Figure 3) with *Asp*718I and *Nru*I digested pInt1 plus the 597 bp *Xba*I-*Sma*I *glaA* terminator fragment from pUC::AMGterm to produce pRaMB17, pRaMB17M, pRaMB17T and pRaMB17Q.

30 DNA primers 12 and 13 (uppercase letters represent sequences in the laccase gene) are used in a PCR reaction to amplify the mutant laccase gene from plasmid pRaMB17T (Figure 4). The PCR is performed in a 50 ml reaction containing 120 ng of plasmid pRaMB17T, 0.05 mM each of dATP, dTTP, dGTP, dCTP, 100 pmol each of primers 12 and

13, 1X *Pwo*I Buffer (Boehringer Mannheim, Indianapolis, IN), 5% (v/v) DMSO, and 2.5 units *Pwo*I (Boehringer Mannheim, Indianapolis, IN). The PCR conditions are 95°C for 3 minutes, 30 cycles each at 95°C for 1 minute, 60°C for 1 minute, and 72°C for 1.5 minutes, and then 72°C for 5 minutes. The PCR reaction mixture is run on an agarose gel and the 2.4 kb DNA laccase band is excised. The DNA is purified by solubilization of the agarose with 3 volumes Qia-ex solubilization buffer (Qiagen, Los Angeles, CA) followed by a Qiaquick PCR spin column according to the manufacturer's directions (Qiagen, Los Angeles, CA). The DNA is recovered in 50 µl of 1 mM EDTA-10 mM Tris pH 8 buffer. A 20 µl aliquot of the DNA is cut in a final volume of 25 µl containing 1X restriction enzyme buffers and restriction enzymes *Pac*I and *Swa*I as suggested by the manufacturer. The reaction mixture is then heated at 80°C for 10 minutes. One ml of the *Pac*I/*Swa*I cut laccase gene is ligated into *Pac*I/*Swa*I cut plasmid pBANE6. The ligation mixture is used to transform *E. coli* strain DH5α. The plasmid containing pBANE6 and the mutant laccase sequences is designated pJeRS31. pJeRS31 is subjected to site-directed mutagenesis using primer 14 to remove the *Swa*I site and add a second ATG using the MORPH Site-Specific Plasmid DNA Mutagenesis Kit according to the manufacturer's instructions (5 Prime 3 Prime, Inc., Boulder, CO) to produce pBANE22T.

A summary of the plasmids is provided in Table 2.

Table 2. pRaMB17 and its derivatives

<u>Vector</u>	<u>MtL protein encoded</u>
pRaMB17	Wild-type MtL
pRaMB17M	MtL with the L513F mutation
pBANE22T	MtL with the triple substitution V509L/S510E/G511A
pRaMB17Q	MtL with the quadruple substitution V509L/S510E/G511A/L513F

Example 2: Transformation of *Aspergillus oryzae* with modified *Myceliophthora thermophila* laccase genes

Methods for co-transformation of *Aspergillus oryzae* are described by Christensen *et al.*, 1988, *Bio/Technology* 6: 1419-1422. For introduction of each of the *Myceliophthora thermophila* laccase expression vectors pRaMB17, pRaMB17M, pBANE22T, and pRaMB17Q into *Aspergillus oryzae* HowB711, equal amounts (approximately 5 µg each) of the laccase expression vector and pToC90 (WO 91/17243) are added to approximately 106 protoplasts

in suspension while pBANE22T is added alone. Transformants are selected on Cove medium (Cove, 1966, *Biochimica Biophysica Acta* 113: 51-56) containing 1 M sucrose, 10 mM acetamide as the sole nitrogen source, and 20 mM CsCl to inhibit background growth. The transformants selected in this way are subsequently screened for the ability to produce laccase on Cove medium containing 1-3 mM ABTS. Cells which secrete active laccase oxidize the ABTS, producing a green halo surrounding the colony. Transformants which produce detectable laccase activity on ABTS plates are purified twice through conidiospores.

Example 3: Expression of modified *Myceliophthora thermophila* laccases

The transformants described in Example 2 are grown in shake flask cultures containing 25 ml of ASPO4 medium (pRAMB17, pRAMB17M, pRAMB17Q) or MY51 medium (pBANE22T) for 4 to 5 days at 37°C. ASPO4 medium is comprised of 1 g of $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$, 2 g of yeast extract, 1 g of MgSO_4 , 2 g of citric acid, 5 g of KH_2PO_4 , 1 g of urea, 2 g of $(\text{NH}_4)_2\text{SO}_4$, 20 g of maltodextrin, and 0.5 ml of trace metals solution per liter. MY51 medium is comprised of 50 g of maltodextrin, 2 g $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 10 g of KH_2PO_4 , 2 g of citric acid, 10 g of yeast extract, 2 g of urea, 1 g of urea, 2 g of $(\text{NH}_4)_2\text{SO}_4$, and 0.5 ml of trace metals solution. The trace metals solution is comprised of 14.3 g of $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$, 2.5 g of $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$, 0.5 g of $\text{NiCl}_2 \cdot 6\text{H}_2\text{O}$, 13.8 g of $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, 8.5 g of $\text{MgSO}_4 \cdot \text{H}_2\text{O}$, and 3.0 g of citric acid per liter of RO water. Culture supernatants are assayed for laccase activity using either ABTS or syringaldazine as a substrate as described below.

Syringaldazine (SGZ) oxidation is determined in MES pH 5.3 buffer or Britten-Robinson buffer, pH 2.7 to 11.0, with 10% ethanol (coming from SGZ stock solution) by monitoring the absorbance change at 530 nm with an extinction coefficient of $65 \text{ mM}^{-1}\text{cm}^{-1}$ (Bauer and Rupe, 1971, *Analytical Chemistry* 43: 421-425) at 20°C. Laccase activity using SGZ as a substrate is assayed by mixing 800 μl of assay buffer (40 μM CuSO_4 -25 mM sodium acetate pH 5.5) with 20 μl of culture supernatant and 60 μl of 0.28 mM syringaldazine in 50% ethanol. The absorbance at 530 nm is measured over time in a UV-VIS spectrophotometer. One laccase unit (LACU) is defined as the amount of enzyme which oxidizes one μmole of substrate per minute at 30°C.

ABTS oxidation is determined at pH 5 in a 96-well plate at 20°C by monitoring the absorbance change at 405 nm with an extinction coefficient of $35 \text{ mM}^{-1}\text{cm}^{-1}$ (Childs and Bardsley, 1975, *Biochemical Journal* 145: 93-103). Laccase activity using ABTS as a

substrate is measured by mixing 20 μ l of culture supernatant with 200 μ l of substrate solution containing 0.275 mg of ABTS per ml of 100 mM sodium acetate pH 5.0.

Shake flask cultures producing high levels of extracellular laccase activity are further evaluated by fermentation. A 1 ml aliquot of a spore suspension (approximately 109 spores) of an *Aspergillus oryzae* transformant expressing the laccase variant of interest is added aseptically to each of several 500 ml shake flasks containing 100 ml of medium comprised of 50 g of Nutriose 725, 2 g of $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 10 g of KH_2PO_4 , 2 g of K_2SO_4 , 0.5 g of $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$, 2 g of citric acid, 10 g of yeast extract, 0.5 ml of trace metals (as described above), and 2 g of urea per liter of tap water (adjusted to pH 6.0 before autoclaving) and incubated at 34°C on a rotary shaker at 200 rpm for about 18 hours. Samples of the shake flask broths are then transferred to a laboratory fermentor containing medium, supplemented with 2 mM $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$, comprised of 30 g of Nutriose, 5 g of yeast extract, 2 g of $(\text{NH}_4)_2\text{HPO}_4$, 2 g of $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 4 g of citric acid, 3 g of K_2SO_4 , 2 g of $\text{CaCl}_2 \cdot \text{H}_2\text{O}$, and 0.5 ml of trace metals solution (as described above) per liter and fed during the course of the fermentation with a medium comprised of 270 g of Nutriose, 30 g of urea, and 15 g of yeast extract per liter. The fermentation is allowed to proceed at 31°C, pH 7, 600-700 rpm for 7 days.

Laccase yields for the "M" (L513F) and "T" (V509L/S510E/G511A) mutants from these fermentations are estimated to be 25% and 40%, respectively, of the wild-type yield. In contrast, the expression yield of mutant "Q" (V509L/S510E/G511A/L513F) is so low that there is insufficient laccase for purification.

Example 4: Purification of modified *Myceliophthora thermophila* laccases

The wild-type, "M", and "T" fermentation broths from Example 3 are cheese-cloth filtered (pH 7.6, 16 mS), filtered through Whatman #2 filter paper, concentrated on a Spiral Concentrator (Amicon) with a S1Y100 membrane (100 kDa MW-CO), and diluted to 0.75 mS with glass distilled water. The washed concentrated broths are loaded onto a Q-Sepharose XK26 (Pharmacia, Uppsala, Sweden) column (120 ml), pre-equilibrated with 10 mM Tris, pH 7.5, 0.7 mS (Buffer A), and active fractions are eluted during the linear gradient with Buffer B (Buffer A plus 2 M NaCl). The active fractions are pooled, adjusted to 1 mS in ionic strength, and subjected to a Mono-Q (Pharmacia, Uppsala, Sweden)

chromatography equilibrated with Buffer A. Laccase preparations with apparent electrophoretic purity are obtained in the run-through fractions.

Example 5: Site-directed mutagenesis of *Rhizoctonia solani* laccase gene

Site-specific mutations are introduced into the *Rhizoctonia solani* laccase *rsl4* gene of the expression plasmid, pJiWa59, using the overlap-extension PCR method (Ho, 1989, *Gene* 77: 51-59) together with the primers listed in Table 3. Primer 15 (SEQ ID NO:22) is used to create pJiWa85 that encodes three amino acid changes ("T": L466V/E467S/A468G) in the laccase coding region (Table 3). PCR amplification with primer 16 (SEQ ID NO:23) results in pJiWa86 which encodes a single amino acid mutation ("M": L470F). For each mutation, a 505 nt *SacI/NorI* fragment is generated by PCR and used to replace the homologous fragment in pJiWa59. PCR-amplified regions of the gene are sequenced to confirm the mutation as well as to ascertain the integrity of the coding region.

Table 3. Primers used for PCR mutagenesis of *rsl4* gene.

Primer 15	C	ATT	GAC	TGG	CAC	<u>G</u> TG	<u>T</u> CG	<u>G</u> GT	GGG	CTC	GCA	CTT	G	
pJiWa85	I	D	W	H	V	S	G	G	L	A	L			
	:	:	:	:					:	:	:	:		
Rsl-wt	H	I	D	W	H	L	E	A	G	L	A	L	V	
rsl4	CAC	ATT	GAC	TGG	CAC	TTG	GAG	GCT	GGG	CTC	GCA	CTT	GTC	
						:	:	:	:		:	:	:	
pJiWa86						L	E	A	G	F	A	L	V	
Primer 16						C	TTG	GAG	GCT	GGG	TTC	GCA	CTT	GTC

Note. The amino acid translation of both the primers and the native gene are shown in italics. Homologous amino acids are noted by a colon between the two sequences. Those nucleotides in the PCR primers which differ from the gene sequence are underlined.

Example 6: Transformation of *Aspergillus oryzae* with the modified *Rhizoctonia solani* *rsl4* genes

Aspergillus oryzae HowB711 is transformed with 8 μ g of pJiWa85 ("T": L466V/E467S/A468G) or pJiWa86 ("M": L470F) together with 2 μ g of pToC90 and *Aspergillus oryzae* HowB104 is transformed with 8 μ g of pJiWa59 (wt) together with 2 μ g

of pToC90 using a standard PEG mediated protocol (Yelton, 1984, *Proceedings of the National Academy of Sciences USA* 81: 1470-1474). The transformants are selected on Minimal medium plates supplemented with 10 mM acetamide and 1 M sucrose. The Minimal medium is comprised of 6.0 g of NaNO₃, 0.52 g of KCl, 1.52 g of KH₂PO₄, 1.0 ml of trace metals solution, 20 g of Nobel Agar (Difco), 20 ml of 50% glucose, 20 ml of methionine (50 g/l), 20 ml of biotin (200 mg/l), 2.5 ml of 20% MgSO₄-7H₂O, and 1.0 ml of mg/ml streptomycin per liter. The agar medium is adjusted to pH 6.5 prior to autoclaving and then glucose, methionine, biotin, MgSO₄-7H₂O, and streptomycin are added as sterile solutions to the cooled autoclaved medium and poured into plates. The trace metals solution is comprised of 0.04 g of Na₂B₄O₇-10H₂O, 0.4 g of CuSO₄-5H₂O, 1.2 g of FeSO₄-7H₂O, 0.7 g of MnSO₄-H₂O, 0.8 g of Na₂MoO₄-2H₂O, and 10 g of ZnSO₄-7H₂O per liter of RO water.

Laccase activity is scored on Minimal medium plates containing 10 mM acetamide and 1 g/l ABTS. Colonies that produce a green halo, indicative of laccase expression, are spore-purified twice.

Example 7: Expression of modified *Rhizoctonia solani* laccases

The spores from transformants of pJiWa59 (wt), pJiWa85 ("T"), and pJiWa86 ("M") described in Example 6 are used to inoculate 15 ml of MY51 medium in 125 ml shake flasks. After 3 days and 5 days growth at 37°C, a 1 ml aliquot is removed from each shake flask and centrifuged at 14,000 g for 5 minutes to remove any mycelia clumps. The supernatants are assayed for ABTS oxidation in 96-well microtiter plates as described below.

ABTS oxidation is determined in MES pH 5.3 buffer or Britten-Robinson buffer at pH 2.7 to 11.0 in a 96-well plate at 20°C by monitoring the absorbance change at 405 nm with an extinction coefficient of 35 mM⁻¹cm⁻¹ (Childs and Bardsley, 1975, *Biochemical Journal* 145: 93-103).

The transformants yielding the highest laccase activity are selected for fermentation and grown as described in Example 3. Laccase yields for the "M" (L470F) and "T" (L466V/E467S/A468G) mutants from these fermentations are estimated to be 17% and 50%, respectively, of the wild-type yield.

Example 8: Purification of *Rhizoctonia solani* modified laccases

The wild-type, "M", and "T" fermentation broths from Example 7 are cheese-cloth filtered (pH 7.6, 16 mS), filtered through Whatman #2 filter paper, and concentrated on a Spiral Concentrator (Amicon) with a S1Y100 membrane (100 kDa MW-CO). The concentrated broths are then applied to a Q Sepharose column (XK26, 120 ml) (Pharmacia, Uppsala, Sweden), preequilibrated with 10 mM Tris pH 7.5, 0.7 mS (Buffer A). Active fractions run through the column during loading and washing. The active fractions are pooled, adjusted to pH 5.3 and applied on a SP-Sepharose column (XK16, 60 ml) (Pharmacia, Uppsala, Sweden), preequilibrated with 10 mM MES pH 5.3 buffer (Buffer C). The majority of activity is eluted by a linear gradient of Buffer D (Buffer C and 1 mM NaCl). The active fractions are adjusted to 20 mS and applied to a Sephadex 200 column (1610, 120 ml) (Pharmacia, Uppsala, Sweden), pre-equilibrated with Buffer E (Buffer C and 0.1 M NaCl). Purified *Rhizoctonia solani* laccase fractions are eluted by Buffer E. A recovery of 1% or 5% and purification of 280- or 150-fold are achieved for mutants "M" and "T", respectively. The "T" mutant shows a three-fold higher yield than the "M" mutant, but two-fold lower yield than the wild-type laccase.

Example 9: Characterization of the modified *Myceliophthora thermophila* laccases and the *Rhizoctonia solani* modified laccases

The Leu/Phe mutation causes a decrease in expression yield. RsL-"M" shows a yield which is three-fold lower than that of RsL-"T", and five-fold lower than that previously obtained for RsL-wild type; while MtL-"M" shows a yield approximately two-fold lower than that observed for MtL-"T" and five-fold lower than that observed for MtL-wild type. When *Polyporus pinsitus* laccase (PpL; U.S. application Serial No. 08/441,147, which is incorporated herein by reference), *Rhizoctonia solani* laccase (including isozyme 1 and 3; WO 95/07988), MtL, *Scytalidium thermophilum* laccase (StL), and *Myrothecium verrucaria* bilirubin oxidase (BiO) are expressed in the same host (HowB104), the yields are in the order of BiO ~ MtL ~ StL > RsL-4 > RsL-1 ~ PpL. Among these laccases, the residue corresponding to the modified Leu in the "M" mutants is: Phe for both PpL and RsL-1; Leu for RsL-4, MtL, and StL; and Met for BiO. It seems that a Phe at this particular position correlates to low expression yield of these laccases in *Aspergillus oryzae* HowB104 and HowB711 strains.

The triple mutations in RsL-mutant "T" (LEA -> VSG), which eliminates the negative charge, decreases activity two orders of magnitude. The triple mutations in MtL-mutant "T" (VSG -> LEA), which creates a negative charge, decreases activity 4-fold. In contrast, the "M" mutants, in which a Leu is replaced by a Phe, exhibit similar activity in comparison to their wild type counterparts. The *Rhizoctonia solani* results are consistent with the hypothesis which correlates the presence of negative charge(s) near the T1 Cu to the specific activity. The effect of the Glu in the selected pentapeptide segment could be attributed to general base-catalysis in which the negatively charged residue facilitates the electron transfer from the substrate to the T1 Cu by perturbing the substrate molecule and/or stabilizing the resulting electron-deficient intermediate or product molecule.

The molecular weights of the mature laccases are used to calculate both extinction coefficients and turnover numbers. The molecular weights are determined from the deduced amino acid sequences of the DNA sequences (Figure 6: SEQ ID NOS:24 and 25, and Figure 7: SEQ ID NOS:26 and 27). Protein concentrations (expressed as subunits) are measured based on the extinction coefficients determined by quantitative amino acid analysis.

Cyclic voltammetry measurements with a Pt electrode show a mid-potential of 0.76 V for $\text{Fe}(\text{dipyridyl})_2\text{Cl}_3$ - $\text{Fe}(\text{dipyridyl})_2\text{Cl}_2$ couple in 8 mM MES pH 5.3. The oxidation of ABTS and SGZ in 8 mM MES pH 5.3 yields a mid-potential of 0.70 and 0.63 V, respectively. The published redox potentials (E°) for the redox couples $\text{Fe}(\text{dipyridyl})_2\text{Cl}_3$ - $\text{Fe}(\text{dipyridyl})_2\text{Cl}_2$, NaI_3 - NaI , and $\text{K}_3\text{Fe}(\text{CN})_6$ - $\text{K}_4\text{Fe}(\text{CN})_6$ are 0.780, 0.536, and 0.433 V, respectively (Kolthoff and Tomsicek, 1936, *Journal of Physical Chemistry* 40: 247-255; O'Reilly, 1973, *Biochimica Biophysica Acta* 292: 509-515; Vanysek, 1992, In Lide, D. R., editor, *Handbook of Chemistry and Physics*, 73rd Edition, pages 8.17-8.22, CRC Press, Boca Raton, Florida). The E° determination for *Rhizoctonia solani* laccase is performed in 8 mM MES pH 5.3 buffer with either 17 μM *Rhizoctonia solani* laccase, 0.2 mM $\text{Fe}(\text{bipyridyl})_2\text{Cl}_2$, and 0.05 - 0.2 mM $\text{Fe}(\text{bipyridyl})_2\text{Cl}_3$, or 71 - 78 μM *Rhizoctonia solani* laccase and 14 - 100 μM ABTS. The E° determination for MtL is performed in 8 mM MES, pH 5.3 with 0.14 mM MtL, 0.02 - 20 mM $\text{K}_3\text{Fe}(\text{CN})_6$, and 2 mM $\text{K}_4\text{Fe}(\text{CN})_6$; as well as with 31 μM MtL, 0.1 mM I_2 , and 5 - 19 mM NaI . Britten-Robinson buffer is used for other pHs. Under various potentials of the solution poised by various concentration ratios of the redox couples, the absorbance changes of laccase in the range of 550-800 nm are monitored and the concentrations of the oxidized copper (II) and reduced copper (I) states are calculated after

the spectral change reaches equilibrium. The concentrations of the redox couples at equilibrium are calculated from the initial concentrations and the concentration changes caused by the interaction with laccase. In the case of measuring E° of *Rhizoctonia solani* laccase with ABTS, the concentration of ABTS cation radical (ABTS⁺) is measured by the absorption at 810 nm (where *Rhizoctonia solani* laccase has no contribution) and then the spectral contribution of ABTS⁺ at 600 nm is subtracted from the observed absorption value in order to assess the spectral change of *Rhizoctonia solani* laccase. Anaerobicity is achieved by repetitive evacuating and argon-flushing the reaction chamber at 4°C.

The mutants exhibit similar chromatographic elution patterns to their wild type counterparts. The purified preparations have a characteristic blue color typical of a laccase and show other typical laccase properties as shown in Table 4. All the mutants can be retained by a 100 kDa MW-CO membrane, indicating a dimeric nature.

Table 4. Properties of *Myceliophthora thermophila* and *Rhizoctonia solani* laccase mutants

	MW*, kDa	λ_{\max} (ε)†	E° at pH 5.3‡
pJiWa59 (wt)	70-85	276 (66), 330sh (4.6), 602 (4.7)	0.73 ± 0.02
pJiWa86 ("M")	70-90	276 (63), 330sh (2.6), 600 (3.7)	0.72 ± 0.02
pJiWa85 ("T")	70-90	276 (63), 330sh (1.7), 600 (4.8)	0.74 ± 0.03
pRaMB17 (wt)	75-90	276 (134), 330sh (8.4), 589 (4.2)	0.47 ± 0.01
pRaMB17M ("M")	70-90	280 (134), 330sh (6.1), 600 (3.8)	0.50 ± 0.01
pBANE22T ("T")	70-90	276 (134), 330sh (4.2), 600 (2.9)	ND□

* Estimated on SDS-PAGE. † Units: l max, nm; ε, mM⁻¹cm⁻¹. Calculated extinction coefficients are used. ‡ in V vs NHE. □Not determined.

K_m and k_{cat} are obtained from the initial rate (v), enzyme concentration (E), and substrate concentration (S) in accordance to the equation $v = k_{cat} ES / (K_m + S)$ by non-linear regression fitting using the Prism program (GraphPad, San Diego, CA). The K_m and k_{cat} for ABTS and SGZ are measured spectroscopically in 8 mM MES-NaOH buffer, pH 5.3; while the values for other substrates are measured by oxygen electrode in Britten-Robinson buffer, pH 5.1 with a Hansatech DW1/AD device (Norfolk, England), with 0.4 - 4 μM laccase in

0.3 - 0.5 ml Britten-Robinson buffer. The O₂ concentration in air-saturated buffer solution is assumed as the same in plain water (0.28 mM).

Tables 5 and 6 summarize the SGZ and ABTS oxidase activities of the mutants. For both *Rhizoctonia solani* laccase and *Myceliophthora thermophila* laccase, more profound difference is observed on the mutant "T" than that on the mutant "M" in comparison with the wild type. Figure 5 shows the pH-activity profiles of the mutants with ABTS and SGZ. For ABTS oxidation, a significant change is seen with RsL-"T", MtL-"M", and MtL-"T". The optimal pH of RsL-"T" is shifted ≥ 1 unit in comparison with the wild type laccase. For SGZ oxidation, an optimal pH at 7 is observed for MtL-"T", in contrast to the range of 5-7 for the wild type laccase. In terms of pH profile, the elimination of the negative charge in RsL-"T" induces a shift of the optimal pH in the acidic direction for SGZ oxidation, probably due to the reduced acidity at the T1 site caused by the Glu removal. The creation of a negative charge in MtL-"T" induces a shift of the optimal pH for activity on the alkaline direction, which could be attributed to the increased acidity at MtL's T1 site caused by the creation of the negative charge.

Table 5. Syringaldazine oxidase activity of the mutants

	LACU*	SOU† (pH _{opt})
RsL wt	4.3	11 (7)
RsL "M"	2.2	4.7 (6)
RsL "T"	0.024	0.048 (7)
MtL wt	42	35 (6)
MtL "M"	24	25 (6)
MtL "T"	2	10 (7)

Activity unit: $\mu\text{mol min}^{-1} \text{mg}^{-1}$. *25 mM sodium acetate pH 5.5, 30°C. † B&R buffer, 20°C, at optimal pH (value in parenthesis).

Table 6. Syringaldazine and ABTS oxidase activity of the mutants

		SGZ		ABTS	
		$K_m, \mu M$	k_{cat}, min^{-1}	$K_m, \mu M$	k_{cat}, min^{-1}
	RsL wt	28 ± 4	550 ± 40	52 ± 6	2500 ± 100
5	RsL "M"	35 ± 4	255 ± 11	125 ± 13	760 ± 30
	RsL "T"	3.9 ± 0.3	1.1 ± 0.1	60 ± 4	20 ± 1
	MtL wt	1.4 ± 0.2	4500 ± 200	110 ± 20	3800 ± 300
	MtL "M"	1.8 ± 0.2	3300 ± 100	43 ± 3	1800 ± 100
	MtL: "T"	0.9 ± 0.2	360 ± 20	11 ± 2	530 ± 20

Claims

What is claimed is:

- 5 1. A mutant of a blue copper oxidase, comprising a mutation selected from the group consisting of (a) a substitution of one or more amino acid residues with other amino acid residues, (b) an insertion of one or more amino acid residues and/or (c) a deletion of one or more amino acid residues, wherein the mutation is carried out at a position which is located no greater than 15Å from a Type I copper site.
- 10 2. A mutant according to claim 1, wherein the position is located no greater than 12Å from a Type I copper site.
3. A mutant according to claim 2, wherein the position is located no greater than 10Å from a Type I copper site.
- 15 4. A mutant according to claim 3, wherein the position is located no greater than 8Å from a Type I copper site.
- 20 5. A mutant according to claim 4, wherein the position is located no greater than 6Å from a Type I copper site.
6. A mutant according to claim 5, wherein the position is located no greater than 4Å from a Type I copper site.
- 25 7. A mutant according to claim 6, wherein the position is located no greater than 2.5Å from a Type I copper site.
8. A mutant according to claim 7, wherein the position is adjacent to an amino acid residue which is a Type I copper site ligand.
- 30

9. A mutant according to claim 7, wherein the amino acid residue which is mutated is a Type I copper site ligand.

10. A mutant of claim 1 in which the oxidase is a bilirubin oxidase.

11. A mutant of claim 1 in which the oxidase is a bilirubin oxidase. a) A mutant of claim 1 in which the oxidase is a phenoxazinone synthase.

12. A mutant of claim 1 in which the oxidase is an ascorbate oxidase.

13. A mutant of claim 1 in which the oxidase is a ceruloplasmin.

14. A mutant of claim 1 in which the oxidase is a nitrite reductase.

15. A mutant of claim 1 in which the oxidase is a laccase.

16. A mutant of claim 15 in which the oxidase is a fungal laccase.

17. A mutant of claim 16 in which the oxidase is a *Rhizoctonia* laccase.

18. A mutant of claim 17 in which the *Rhizoctonia* laccase comprises the amino acid sequence 466LEAGL470.

19. A mutant of claim 16 in which the oxidase is a *Myceliophthora* laccase.

20. A mutant of claim 19 in which the *Myceliophthora* laccase comprises the amino acid sequence 509VSGGL513.

21. A mutant of claim 1 in which (a) a neutral amino acid residue is substituted with a negative amino acid residue or (b) a positive amino acid residue is substituted with a negative or neutral amino acid residue.

22. A mutant of claim 1 in which a phenylalanine is substituted with another amino acid residue.

23. A mutant of claim 22 in which the other amino acid residue is a leucine.

24. A mutant of claim 1 in which (a) a neutral amino acid residue is substituted with a positive amino acid residue or (b) a negative amino acid residue is substituted with a positive or neutral amino acid residue.

25. A mutant of claim 1 in which leucine or phenylalanine is substituted with a neutral residue selected from the group consisting of histidine, serine, threonine, tyrosine, cysteine, and methionine.

26. A mutant of claim 1 which is modified in a segment corresponding to 416VIELNITGGADHPI429 of *Rhizoctonia solani* laccase and 421ENDPGAPFTLPHPM433 of *Myceliophthora thermophila* laccase.

27. A mutant of claim 1 which is modified in a segment corresponding to 474GPWFVHCHIDWHLEAGLALVF494 of *Rhizoctonia solani* laccase and 497GAWLFHCHIAWHVSGGLGV515 of *Myceliophthora thermophila* laccase.

28. A mutant of claim 1 which is modified in a segment corresponding to 356VSLNLAIGRSTVDGIL371 of *Rhizoctonia solani* laccase and 361VTLDTTGTPLFVWQVN376 of *Myceliophthora thermophila* laccase.

29. A mutant of claim 1 which is modified in a segment corresponding to 303LDPTNVFAVL312 of *Rhizoctonia solani* laccase and 308AIFHYAGAPG317 of *Myceliophthora thermophila* laccase.

30. A mutant of claim 1 which is modified in a segment corresponding to 217INVKRGKRYR226 of *Rhizoctonia solani* laccase and 222GRRHRLRLIN231 of *Myceliophthora thermophila* laccase.

31. A mutant of claim 1 which is modified in a segment corresponding to 465LEAGL472 of *Rhizoctonia solani* laccase.

5 32. A mutant of claim 1 which is modified in a segment corresponding to 466LEAGL470 of *Rhizoctonia solani* laccase.

33. A mutant of claim 1 which is modified by at least two amino acid residues.

34. A mutant of claim 33 which is modified by at least 3 amino acid residues.

10 35. A mutant according to claim 1, wherein the mutation is a substitution.

36. A nucleic acid construct comprising a nucleic acid sequence encoding the mutant of claim 1.

15 37. A host cell comprising the construct of claim 36.

38. A method for producing a mutant of a blue copper oxidase, comprising culturing a host cell of claim 37 under conditions conducive to expression of the mutant and recovering the mutant.

20

1/15




FIG. 1

SUBSTITUTE SHEET (RULE 26)

2/15




FIG.2A

3/15




FIG.2B

4/15




FIG.3

5/15






FIG.4



SUBSTITUTE SHEET (RULE 26)

6/15




FIG. 5B




FIG. 5D




FIG. 5A




FIG. 5C

7/15

```

      87      96      105      114      123      132
5'  ATG CTT TCT AGC ATT ACC CTC CTA CCT TTG CTC GCT GCG GTC TCA ACC CCC GCC
    ---
    M  L  S  S  I  T  L  L  P  L  L  A  A  V  S  T  P  A

      141      150      159      168      177      186
TTT GCT GCC GTC CGC AAC TAT AAG TTC GAC ATC AAG AAC GTC AAT GTC GCT CCC
    ---
    F  A  A  V  R  N  Y  K  F  D  I  K  N  V  N  V  A  P

      195      204      213      222      231      240
GAT GGC TTT CAG CGC TCT ATC GTC TCC GTC AAC GGT TTA GTT CCT GGC ACG TTG
    ---
    D  G  F  Q  R  S  I  V  S  V  N  G  L  V  P  G  T  L

      249      258      267      276      285      294
ATC ACG GCC AAC AAG GGT GAC ACC TTG CGC ATT AAT GTC ACG AAT CAA CTC ACG
    ---
    I  T  A  N  K  G  D  T  L  R  I  N  V  T  N  Q  L  T

      303      312      321      330      339      348
GAC CCT AGT ATG CGT CGT GCC ACA ACG ATT CAT TGG CAT GGA TTG TTC CAA GCT
    ---
    D  P  S  M  R  R  A  T  T  I  H  W  H  G  L  F  Q  A

      357      366      375      384      393      402
ACT ACC GCC GAC GAG GAT GGC CCC GCA TTC GTC ACG CAA TGC CCT ATT GCG CAA
    ---
    T  T  A  D  E  D  G  P  A  F  V  T  Q  C  P  I  A  Q

      411      420      429      438      447      456
AAT TTG TCC TAT ACA TAC GAG ATC CCA TTG CGC GGC CAA ACA GGA ACC ATG TGG
    ---
    N  L  S  Y  T  Y  E  I  P  L  R  G  Q  T  G  T  M  W

      465      474      483      492      501      510
TAT CAC GCC CAT CTT GCG AGT CAA TAT GTC GAT GGA TTG CGA GGC CCT TTG GTC
    ---
    Y  H  A  H  L  A  S  Q  Y  V  D  G  L  R  G  P  L  V

      519      528      537      546      555      564
ATC TAT GAT CCA AAC GAC CCA CAC AAG TCG CGC TAC GAC GTG GAT GAT GCG AGC
    ---
    I  Y  D  P  N  D  P  H  K  S  R  Y  D  V  D  D  A  S

```

FIG.6A

SUBSTITUTE SHEET (RULE 26)

8/15

573	582	591	600	609	618
ACA GTA GTC ATG CTT	GAG GAC TGG	TAC CAT ACT	CCG GCA CCC	GTT CTA GAA	AAG

T V V M L	E D W Y H	T P A P V	L E K		
627	636	645	654	663	672
CAA ATG TTC TCG ACT	AAT AAC ACC	GCT CTG CTC	TCT CCT GTT	CCG GAC TCG	GGT

Q M F S T	N N T A L	L S P V P	D S G		
681	690	699	708	717	726
CTT ATC AAT GGC AAA	GGG CGC TAT	GTG GGC GGT	CCC GCA GTT	CCC CGG TCA	GTA

L I N G K	G R Y V G	G P A V P	R S V		
735	744	753	762	771	780
ATC AAC GTA AAA CGT	GGG AAA CGA	TAT CGC TTG	CGC GTA ATC	AAC GCT TCT	GCT

I N V K R	G K R Y R	L R V I N	A S A		
789	798	807	816	825	834
ATC GGG TCG TTT ACC	TTT TCG ATC	GAA GGA CAT	AGT CTG ACT	GTC ATT GAG	GCC

I G S F T	F S I E G	H S L T V	I E A		
843	852	861	870	879	888
GAT GGG ATC CTG CAC	CAG CCC TTG	GCT GTT GAC	AGC TTC CAG	ATT TAC GCT	GGA

D G I L H	Q P L A V	D S F Q I	Y A G		
897	906	915	924	933	942
CAA CGC TAC TCT GTC	ATC GTT GAA	GCC AAC CAA	ACC GCC GCC	AAC TAC TGG	ATT

Q R Y S V	I V E A N	Q T A A N	Y W I		
951	960	969	978	987	996
CGT GCA CCA ATG ACC	GTT GCA GGA	GCC GGA ACC	AAT GCA AAC	TTG GAC CCC	ACC

R A P M T	V A G A G	T N A N L	D P T		
1005	1014	1023	1032	1041	1050
AAT GTC TTT GCC GTA	TTG CAC TAC	GAG GGA GCG	CCC AAC GCC	GAA CCC ACG	ACG

N V F A V	L H Y E G	A P N A E	P T T		

FIG.6B

SUBSTITUTE SHEET (RULE 26)

9/15

1059	1068	1077	1086	1095	1104
GAA CAA GGC AGT GCT ATC GGT ACT GCA GTG GTT GAA GAG AAC GTG CAT GCG CTC					
-----	-----	-----	-----	-----	-----
E Q G S A I G T A L V E E N L H A L					
1113	1122	1131	1140	1149	1158
ATC AAC CCT GGC GCT CCG GGC GGC TCC GCT CCC GCA GAC GTT TCC CTC AAT CTT					
-----	-----	-----	-----	-----	-----
I N P G A P G G S A P A D V S L N L					
1167	1176	1185	1194	1203	1212
GCA ATT GGG CGC AGC ACA GTT GAT GGG ATT CTT AGG TTC ACA TTT AAT AAC ATC					
-----	-----	-----	-----	-----	-----
A I G R S T V D G I L R F T F N N I					
1221	1230	1239	1248	1257	1266
ATC TAC GAG GCT CCT TCG TTG CCC ACG CTC TTG AAG ATT TTG GCA AAC AAT GCG					
-----	-----	-----	-----	-----	-----
K Y E A P S L P T L L K I L A N N A					
1275	1284	1293	1302	1311	1320
AGC AAT GAC GCC GAT TTC ACG CCA AAT GAG CAC ACT ATC GTA TTG CCA CAC AAT					
-----	-----	-----	-----	-----	-----
S N D A D F T P N E H T I V L P H N					
1329	1338	1347	1356	1365	1374
AAA GTT ATC GAG CTC AAT ATC ACC GGA GGT GCA GAC CAC CCT ATC CAT CTC CAC					
-----	-----	-----	-----	-----	-----
I V I E L N I T G G A D H P I H L H					
1383	1392	1401	1410	1419	1428
GGC CAT GTG TTT GAT ATC GTC AAA TCA CTC GGT GGT ACC CCG AAC TAT GTC AAC					
-----	-----	-----	-----	-----	-----
G H V F D I V K S L G G T P N Y V N					
1437	1446	1455	1464	1473	1482
CCG CCA CGC AGG GAC GTA GTT CGT GTC GGA GGC ACC GGT GTG GTA CTC CGA TTC					
-----	-----	-----	-----	-----	-----
P P R R D V V R V G G T G V V L R F					
1491	1500	1509	1518	1527	1536
AAG ACC GAT AAC CCA GGC CCA TGG TTT GTT CAC TGC CAC ATT GAC TGG CAC TTG					
-----	-----	-----	-----	-----	-----
K T D N P G P W F V H C H I D W H L					

FIG.6C

SUBSTITUTE SHEET (RULE 26)

10/15

1545	1554	1563	1572	1581	1590
GAG GCT GGG CTC	GCA CTT GTC	TTT GCC GAG	GCC CCC AGC	CAG ATT CGC	CAG GGT
---	---	---	---	---	---
E A G L	A L V	F A E	A P S	Q I R	Q G
1599	1608	1617	1626	1635	1644
GTC CAG TCG CTG	CAG CCC AAC	AAT GCC TGG	AAC CAG CTC	TGC CCC AAG	TAC GCG
---	---	---	---	---	---
V Q S V	Q P N	N A W	N Q L	C P K	Y A
1653	1662				
GCT CTT CCT CCC	GAT TTG CAG T	3'			
---	---	---			
A L P P	D L Q				

FIG.6D

11/15

gctagcttcttttggtcacgctcgtttttcgccccccctctctcaacccccctgagtagtcggctaagcgatcctca 80
 atctggtcttgtgaggtcacgtcctccagcagatgacagttcatcgagcgagtgatctccaccaccagaaggaggggg 160
 gatgcgcgcatgctccaacataccctggtgtcgctagagacgtcgcgccatcagcccttttcatcacaccgagcacgtcca 240
 cggaccggctcctttcaccccccggtcctccggaggattgagtcacgatatatttcgggatgtgggaaggaggagaaaagg 320
 agggggaggggcggaacacatgttgatacgagctgcgccctttccaacatcgagaacaggaaagtcgttggtgcggc 400
 cgtaatgtctataaaacgaggctccttctcgctcgacttgctcaggttctctctctcgtccacaccaagccagtcctt 480
 gcctgagccacctgagccaccttcaactcatctctcagtcagtcagtcattgacattgtgtctctcttctctatcgag 560
 tcggcttcccgcccttcaccacaacATGAAGTCTTCATCAGCGCGGACGCTTTGGTGGGCATTCTACCCCTAGC 640
 MetLysSerPheIleSerAlaAlaThrLeuValGlyIleLeuThrProSer -30
 GTTGCTGCTGCCCCCTCCATCCACCCCTGAGCAGCGGACCTGCTCGTCCGATCAGGAGAGGGAGGAGCCGTGAA 720
 ValAlaAlaProProSerThrProGluGlnArgAspLeuValProIleThrGluArgGluAlaAlaValLy -3
 GGCTCGCCAGCAGAGCTGCAACACCCCCAGCAACCGGGGTGCTGGACTGACGGATACGAGATCAACACCGACTACGAAG 800
 sAlaArgGlnGlnSerCysAsnThrProProSerAsnArgAlaCysTrpThrAspGlyTyrAspIleAsnThrAspTyrGluV 25
 TGGACAGCCCCGGACACGGGTGTGTTGGCGCGgtgagtgctctcgtaattacgcttcggcgagttgcgcatatatta 880
 aIAspSerProAspThrGlyValValArgPro 35

FIG. 7A

12/15

FIG. 7B

13/15

CAGCTCGGCGCAGAGCTGGTGGAACTCACCAAGAACTCGGGCGGCCCTTCAGCGACAACGTCTCTTCAACGGCACGG 1680
 rSerSerAlaAspGluLeuValGluLeuThrLysAsnSerGlyAlaProPheSerAspAsnValLeuPheAsnGlyThrA 204

 CCAAGCACCCGGAGACGGGGCGAGTACGCCAACGTGACGCTCACCCCGGGCGGCGCACCGCTGCGCCTGATC 1760
 laLysHisProGluThrGlyGluGlyGluTyrAlaAsnValThrLeuThrProGlyArgArgHisArgLeuArgLeuIle 230

 AACACGTGGTTCGAGAACCACCTCCAGGTCCTCGTCAACCACACCATGTGCATCATCGCCGCGACATGGTGCCCGT 1840
 AsnThrSerValGluAsnHisPheGlnValSerLeuValSerLeuValAsnHisThrMetCysIleIleAlaAlaAspMetValProVal 257

 CAACGCCATGACGGTCGACAGCCTCTTCCTCGGGCTCGGCCAGCGTTACGATGTGTCTCATCGAAGCCAAACCGAACGCCCG 1920
 lAsnAlaMetThrValAspSerLeuPheLeuGlyValGlyGlnArgTyrAspValValIleGluAlaAsnArgThrProG 284

 GGAATACTGGTTTAACGTGCACATTTGGCGGGCGCTGCTCGGGGGCTCCAGGAATCCCTACCCGGCGCCATCTTC 2000
 lYAsnTyrTrpPheAsnValThrPheGlyGlyGlyLeuLeuCysGlyGlySerArgAsnProTyrProAlaAlaIlePhe 310

 CACTAGCGCGGCGCCCGGGCGGCCCGCCACGGACGAGGGCAAGGCCCGGTGACCCACAACCTGCCTGGACCTCCGCCAA 2080
 HisTyrAlaGlyAlaProGlyGlyProProThrAspGluGlyLysAlaProValAspHisAsnCysLeuAspLeuProAs 337

 CCTCAAGCCCGTCGTGGCCCGCAGCTGCCCCCTGAGCGGCTTCGCCAAGCGGGCGCACACACGCTCGACGTCACCCCTCG 2160
 nLeuLysProValValAlaArgAspValProLeuSerGlyPheAlaLysArgAlaAspAsnThrLeuAspValThrLeuA 364

 ACACCACGGGCACGCCCTGTTCGTCTGGAAGGTCAACGGCAGCGCCCATCAACATCGACTGGGGGAGGGCGCTCGTCGAC 2240
 spThrThrGlyThrProLeuPheValTrpLysValAsnGlySerAlaIleAsnIleAspTrpGlyArgAlaValValAsp 390

 TAGTCTCTACGCAGAACACCAGCTTCCACCCGGGTACAACATTGTTCGAGGTGAACGGAGCTGATCAGgttaagaaaaag 2320
 TyrValLeuThrGlnAsnThrSerPheProProGlyTyrAsnIleValGluValAsnGlyAlaAspGln 413

FIG. 7C

14/15

gggaccgcagggtgctgctgaagtacaccttgctgcgcctcctgttcttcttaataactacctcccaaccctcccc 2400
 ctaattaattcactttaagccgatcaagactgaccgagccccctctctttgcagTGGTCGTACTGGTTGATCGAGAAC 2480
 TrpSerTyrTrpLeuIleGluAsn 421
 GATCCGGGGCACCTTTACCCCTACCGCATCCGATGCACCTGCACgtaagttggatacatatatatatatatacat 2560
 AspProGlyAlaProPheThrLeuProHisProMetHisLeuHis 436
 tgctttcctgctgcctcccttaataaaattaaataaaccaaaataaacaataaagGGCCACGACTTTTACGTGCTGG 2640
 GlyHisAspPheTyrValLeuG 444
 GCCGCTGCCCGACGAGTGGCGGCATCCAACGAGCGGCACGTGTTCCGATCCGGCGGGGACGGGGCTGCTGAGCGGG 2720
 LysArgSerProAspGluSerProAlaSerAsnGluArgHisValPheAspProAlaArgAspAlaGlyLeuLeuSerGly 470
 GCCAACCCCTGTGCGGGGACGTGTCGATGCTGCCGGCGTTCGGGTGGGTGGTGTCTTCCGGGGCCGACACCCGGG 2800
 AlaAsnProValArgArgAspValSerMetLeuProAlaPheGlyTrpValValLeuSerPheArgAlaAspAsnProGly 497
 CGCCTGGCTGTTCCACTGCCACATCGCCTGGCAGCTCTCGGGCGGCTGGGGCGTCTTACCTTCGAGCGCGCCGACGACC 2880
 yAlaTrpLeuPheHisCysHisIleAlaTrpHisValSerGlyGlyLeuGlyValValTyrLeuGluArgAlaAspAspL 524
 TGGCGGGGGCGTCTGGAGCGCGACCGCGACCTCGACCGCTCTGGCGCGACTGGCGCGCTACTGGCCTACCAAC 2960
 euArgGlyAlaValSerAspAlaAspAlaAspAlaAspArgLeuCysAlaAspTrpArgArgTyrTrpProThrAsn 550
 CCCTACCCCAAGTCCGACTCGGGCTCAAACACCGCTGGGTGCGAGGAGGGGAGTGGCTGGTCAAGGCGtgagcgaagga 3040
 ProTyrProLysSerAspSerGlyLeuLysHisArgTrpValGluGluGlyGluTrpLeuValLysAla*** 573

FIG. 7D

15/15

ggaaaaaggaaacaaagaggggggggctagttcctatttttgctttttttttgttcttgcttgctggcgg 3120
ttccctggtaaaaggagagggggccccaagtgcgagtgggtgtgtgatcgggtaaatattatcaagagatct 3192

FIG. 7E

INTERNATIONAL SEARCH REPORT

Application No
US 96/14087A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/53 C12N9/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, no. 2, 15 January 1988, MD US, pages 885-896, XP002023112 U.A.GERMANN ET AL.: "Characteristics of two allelic forms of Neurospora crassa laccase" see the whole article, especially figure 4. ---	1-9,15, 16, 21-25, 33-38
X	JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 25, 5 September 1990, MD US, pages 15224-15230, XP002023164 Y.KOJIMANI ET AL.: "Cloning, sequence analysis, and expression of ligninolytic phenoloxidase genes of the white-rot basidiomycete Coriolus hirstus" see figure 3 --- -/--	1-9,15, 16, 21-25, 33-38

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

20 January 1997

Date of mailing of the international search report

31.01.97

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Cupido, M

INTERNATIONAL SEARCH REPORT

Application No

PCT/US 96/14087

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,95 07988 (NOVO NORDISK A/S) 23 March 1995 see the whole document, especially SEQ ID NOs 13 and 14 ---	1-9, 15-18, 21,33-38
X	WO,A,92 01046 (VALTION TEKNILLINEN TUTMIKUSKEKKESKUS) 23 January 1992 see the whole document ---	1-9,15, 16, 21-25, 33-38
P,X	WO,A,95 33836 (NOVO NORDISK BIOTECH, INC.) 14 December 1995 see the whole document, especially SEQ ID NOs 1 and 2 ---	1-9,15, 19-25, 33-38
A	EP,A,0 506 431 (WAKO PURE CHEMICAL INDUSTRIES LTD) 30 September 1992 see the whole document ---	1-9,12
A	CELL, vol. 76, no. 2, 28 January 1994, NA US, pages 403-410, XP002023113 C.ASKWITH ET AL.: "The FET3 gene of S.cerevisiae encodes a multicopper oxidase required for ferrous iron uptake" see figure 5 -----	1-9

INTERNATION SEARCH REPORT

Application No
/US 96/14087

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9507988	23-03-95	US-A- 5480801 AU-A- 7833694 CA-A- 2171288 CN-A- 1133067 EP-A- 0719337 FI-A- 961250	02-01-96 03-04-95 23-03-95 09-10-96 03-07-96 18-03-96
WO-A-9201046	23-01-92	NONE	
WO-A-9533836	14-12-95	AU-A- 2656595	04-01-96
EP-A-0506431	30-09-92	CA-A- 2064304 JP-A- 5268950	29-09-92 19-10-93